Every Peptide Question, Answered Honestly

Research peptides occupy a legal middle zone in the United States. They are not controlled substances under the Controlled Substances Act, and possession by researchers is not prohibited. They are, however, not approved for human consumption by the FDA outside of specific pharmaceutical formulations (e.g., Semaglutide approved as Ozempic or Wegovy). Vendors legally sell them under a Research-Use-Only framework — 'not for human consumption, not evaluated by FDA.' Buying and possessing peptides for research is permitted; marketing therapeutic claims or operating as an unlicensed medical practitioner is not. Researchers should understand they are working outside the protective infrastructure of FDA-approved pharmaceuticals and accept the associated context. State law, import regulation, and athletic-body rules (WADA, NCAA, professional leagues) add further layers that vary by situation.

For pharmaceutical formulations — Ozempic, Wegovy, Mounjaro, Zepbound — yes, a prescription from a licensed clinician is required in the US. For research-use-only peptides sold through research supply vendors, no prescription is required at the point of purchase; these are sold under the RUO framework that does not require prescription infrastructure. Some researchers work with longevity or functional-medicine clinicians who prescribe compounded pharmaceutical versions; others operate entirely in the RUO space with self-directed research protocols. The tradeoff is well-understood: pharmaceutical pathway means clinician oversight, insurance coverage (sometimes), and pharmaceutical-grade supply chain but higher cost and narrower compound selection. RUO pathway means broader selection, lower cost, and full self-responsibility for dose math, sourcing verification, and protocol safety.

Safe sourcing is the single most load-bearing decision in peptide research. A legitimate vendor publishes per-batch third-party Certificates of Analysis including both HPLC purity and mass spectrometry identity confirmation, maintains cold-chain shipping, operates transparent return and batch-tracking policies, and has a multi-year track record verifiable through community channels. Red flags: COAs without batch numbers, HPLC-only results missing MS identity confirmation, vendors accepting only cryptocurrency with no other payment rails, extremely low prices compared to market median, and absent or scrubbed customer communication history. DoseCraft maintains vendor trust scoring directly inside the app so researchers can see sourcing quality context at protocol-design time rather than trusting forum-driven recommendations that are frequently vendor-shill contaminated.

Research-grade peptides are produced to high purity specifications (typically ≥98% HPLC) but are sold under Research-Use-Only framing without FDA evaluation, GMP certification, or pharmacy distribution infrastructure. Pharma-grade peptides — Ozempic, Mounjaro, compounded Semaglutide from 503A pharmacies — are produced under GMP, carry full FDA or state-board oversight, and come with pharmacist verification and insurance reimbursement pathways. The active molecule can be identical between the two grades. The differences are in quality-assurance infrastructure, supply-chain auditing, regulatory wrapper, and legal use case. Research-grade is appropriate for laboratory research contexts; pharma-grade is the only legally appropriate channel for clinical therapeutic use. Researchers should not assume research-grade is 'worse' in molecular quality — many batches test at equivalent purity — but the regulatory and QA infrastructure around pharma-grade is meaningfully different.

Lyophilized (freeze-dried) peptides are typically stable at refrigerator temperature (2–8°C) for 1–3 years and at room temperature for weeks, though compound-specific stability varies. Always store in the original sealed vial, shielded from light, inside the refrigerator — not the freezer, which can damage some compounds through freeze-thaw cycles unless explicitly specified. Reconstituted peptides have dramatically shorter shelf life: most retain potency for 30–60 days refrigerated in bacteriostatic water, with some fragile compounds degrading faster. Never freeze reconstituted peptides unless the compound documentation specifically supports it. Track reconstitution date per vial — DoseCraft's inventory tool logs reconstitution dates automatically and flags when a vial is approaching its potency window boundary. If a reconstituted solution develops cloudiness, discoloration, or visible particles, discard it.

Reconstitution is the process of dissolving a lyophilized (freeze-dried) peptide powder into bacteriostatic water to produce an injectable solution. The process: swab both vial tops with alcohol, draw a measured volume of bacteriostatic water into an insulin syringe, inject the water down the side wall of the peptide vial (not directly onto the powder, which foams), gently swirl without shaking, and allow the solution to fully dissolve. Reconstitution volume determines final concentration in mcg per mL, which drives every subsequent dose calculation. A 5mg vial reconstituted with 2mL BAC water produces a 2.5mg/mL solution — a 0.5mg dose is 0.2mL, which equals 20 units on a U-100 insulin syringe. DoseCraft's reconstitution calculator handles this conversion automatically across arbitrary vial sizes and reconstitution volumes.

Yes. BAC water is shorthand for bacteriostatic water for injection (BWFI) — sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth, allowing a multi-dose vial to be accessed repeatedly over weeks of refrigerated storage without becoming contaminated. This is the standard diluent for multi-dose peptide vials. Plain sterile water for injection (SWFI) and sterile saline (0.9% sodium chloride) lack the bacteriostatic preservative and are designed for single-use applications — using them in multi-dose peptide research creates a documented contamination vector. BAC water is sold by research supply houses and some pharmacies in 30mL multi-dose vials, typically for a few dollars per vial, and is stored at room temperature. A single BAC vial reconstitutes many peptide vials, so cost is trivial relative to the peptide itself.

For single-use reconstitution where the entire vial will be injected at once, sterile saline works. For multi-dose vials — which is the overwhelmingly common case in peptide research — saline is a documented contamination risk because it lacks the benzyl alcohol preservative that prevents bacterial growth between accesses. Using saline in a multi-dose vial that is accessed across weeks creates an environment where contaminants can proliferate. Practitioner consensus is unambiguous: use BAC water for any peptide vial that will be accessed more than once. The cost difference is negligible and the contamination risk is not. For peptides that specifically require non-preserved diluent (rare, compound-specific), follow the compound's documented reconstitution guidance. DoseCraft's compound library includes reconstitution recommendations per compound.

Converting a mass dose to insulin syringe units requires three inputs: target dose in mg or mcg, vial peptide mass, and reconstitution volume. The formula is: dose volume (mL) = target dose (mg) ÷ concentration (mg/mL), and units = dose volume (mL) × 100 on a standard U-100 syringe. Example: a 5mg Semaglutide vial reconstituted with 2mL BAC water yields 2.5mg/mL. A 0.25mg starting dose equals 0.25 ÷ 2.5 = 0.1mL = 10 units. Keep syringe type consistent — U-40 syringes calibrate differently and mixing unit scales is a primary dose-error source. DoseCraft's reconstitution calculator performs this conversion automatically and produces a per-vial dosing table so researchers don't have to recompute each injection.

Half-life determines how often a compound must be redosed to maintain steady-state tissue exposure and how long it remains active after the last dose. A short half-life compound like BPC-157 at roughly 4 hours systemic requires multiple daily injections to sustain meaningful tissue presence; a long half-life compound like Tirzepatide at ~120 hours supports once-weekly dosing. Ignoring half-life math produces two characteristic failure modes: trough concentrations that drop below functional threshold between doses (creating dead windows where the compound is technically present but not engaging receptors), and unexpected carryover when starting a new protocol too soon after discontinuing the previous one. DoseCraft's PK-aware engine models half-life decay per compound so researchers can see exposure between injections rather than guessing from a static milligram-per-week target.

Established practitioner protocols for BPC-157 typically range 250–500mcg per dose, administered subcutaneously once or twice daily, with injection placed as close to the target tissue as practical. Protocol duration is commonly 4–6 weeks during active repair windows with off-periods between cycles. Because BPC-157 has a relatively short systemic half-life, split dosing (morning + evening) maintains tissue exposure better than a single daily dose at the same total mass. Stacking with TB-500 at 2–2.5mg per week is documented in practitioner protocols for more complex repair targets. As with all research peptides, this is research-context information — not medical advice — and individual protocol decisions should reflect the researcher's broader context including baseline health markers, target injury, and any concurrent interventions. DoseCraft's compound library provides full practitioner-sourced protocol detail inside the app.

Cycle length varies by compound class. Growth-hormone-axis peptides (GHRH analogs, growth hormone secretagogues) are commonly cycled 8–12 weeks on with a 4-week off-period to preserve receptor sensitivity. Repair peptides like BPC-157 are typically run only during injury-recovery windows rather than continuously. GLP-1 analogs used in metabolic research are increasingly run indefinitely with dose taper rather than hard cycling, because the GLP-1 receptor resists desensitization better than originally modeled. Nootropic peptides are usually cycled 2–4 weeks on with equivalent off-periods because subjective edge tends to blunt over time. The core cycling question is whether a specific compound produces meaningful receptor desensitization at the target dose — which is compound-specific and dose-specific, not a universal rule. DoseCraft's protocol engine surfaces cycle-length guidance per compound based on practitioner corpus data.

Stacking is safe when mechanisms are complementary rather than redundant and when interaction profiles are understood. Classic well-supported stacks include BPC-157 plus TB-500 (complementary repair mechanisms), GHRH analog plus growth hormone secretagogue (different receptors producing synergistic GH pulse), and Semaglutide plus Cagrilintide (dual appetite pathways). Unsafe stacking compounds two mechanisms that burden the same organ system, overlap on side-effect profile without incremental benefit, or push total tissue exposure beyond practitioner-validated ranges for a single compound. Running two GH-axis secretagogues simultaneously, for example, doesn't double the GH pulse — it adds toxicity exposure without commensurate benefit. DoseCraft's interaction checker models overlap mathematically across 2–5 compound stacks and flags redundant versus complementary combinations before protocol finalization.

Most research peptides default to subcutaneous (SubQ) administration because the fat layer provides predictable moderate absorption, minimal injection discomfort with a small insulin needle, and easy site rotation across multiple body locations. SubQ is sufficient for GLP-1 analogs, healing peptides, and most compound classes. Intramuscular (IM) injection is used when faster absorption is specifically desired or for oil-based compounds that don't absorb well from fat tissue. IM requires a longer 1–1.5 inch needle and is more uncomfortable than SubQ. Some repair-oriented protocols prefer IM injection close to the target tissue for a local effect, though the evidence for meaningful pharmacokinetic benefit over SubQ for most peptides is limited. When in doubt, default to SubQ with a standard insulin syringe — it is appropriate for nearly every water-based research peptide.

Injection sites should rotate every session — not every few days, and not after visible tissue changes appear. Repeated injection at the same location causes local inflammation, scar tissue formation, and lipohypertrophy (lumpy fat tissue with unpredictable absorption). Established protocols cycle across at least 4–6 distinct sites on a predictable rotation: left abdomen, right abdomen, left thigh, right thigh, alternating daily, for example. Sites should be at least one inch apart from a previously used spot within the same rotation cycle and two inches away from anatomical landmarks like the navel. Rotation introduces small session-to-session absorption variance, which is a minor protocol cost in exchange for long-term tissue health and preserved absorption consistency across a multi-month research window. DoseCraft's logging interface tracks site rotation automatically and flags when rotation patterns become too concentrated.

Timing varies by mechanism. Growth hormone secretagogues and GHRH analogs are typically dosed before bed on an empty stomach to sync with natural nocturnal GH pulse timing and to avoid competition with food-induced insulin spikes that blunt GH release. GLP-1 analogs are timing-insensitive for long-half-life versions (weekly Semaglutide or Tirzepatide can be injected any day at any time consistently) but morning dosing can help manage early-cycle nausea by concentrating side-effect exposure during waking hours. Healing peptides are commonly split into morning and evening doses to maintain steady tissue exposure across the day. The meta-principle: timing should support the compound's mechanism, match the researcher's lifestyle for compliance, and remain consistent within a cycle so timing doesn't become a confounding variable in outcome analysis.

Injected peptides bypass the gastrointestinal tract entirely, so food status is not a direct PK variable for SubQ or IM administration. The indirect interaction that matters: food intake triggers insulin release, which can dampen endogenous GH pulse response to growth-axis peptides. This is why GHRH analogs and growth hormone secretagogues are conventionally administered on an empty stomach with no food for 1–2 hours before or 30 minutes after. For GLP-1 analogs, food-timing interaction is more nuanced — the compounds slow gastric emptying, which changes food tolerance during titration, but injection timing relative to meals does not meaningfully affect plasma PK of the compound itself. For most other research peptides (healing peptides, nootropics, longevity peptides), food status is not a PK factor and dosing can occur at any point relative to meals.

Tapering depends on the compound's mechanism and the researcher's adaptation state. GLP-1 analogs benefit from gradual dose reduction — stepping down in the same increments used during titration — to minimize rebound appetite response and metabolic adjustment. Growth-axis peptides are typically discontinued directly at cycle end; tapering adds little benefit because endogenous HPA-axis signaling resumes within days. Long-half-life compounds self-taper through natural plasma decay — discontinuing a weekly Tirzepatide dose produces roughly a 50% plasma drop at week one, 25% at week two, and functional clearance around week four, so an abrupt stop behaves pharmacokinetically like a slow taper. Repair peptides and nootropic peptides generally don't require tapering because they don't produce significant dependent receptor adaptation at research doses. DoseCraft's cycle-end tools generate taper schedules per compound when tapering is mechanistically useful.

Vendor verification is a multi-signal pattern-match, not a single checkbox. Confirm per-batch third-party COAs with both HPLC purity and mass spectrometry identity data. Verify the COA is genuine by confirming the testing laboratory actually performed the test (contact the lab directly with the batch number and test date). Check community reports across multiple independent forums and look for multi-year track record rather than short-term reputation. Examine payment-method legitimacy — reputable vendors typically support multiple payment rails, not only cryptocurrency. Confirm cold-chain shipping practices and return policies for damaged batches. Look for transparent customer communication — persistent response delays or generic evasive answers are a warning signal. DoseCraft's vendor trust score aggregates these signals so researchers see a composite trust rating at the moment of compound selection rather than conducting separate per-vendor investigations.

A Certificate of Analysis (COA) is a third-party laboratory report documenting the purity, identity, and mass of a specific peptide batch. A legitimate COA is issued by an independent laboratory (not the vendor's internal lab), lists the specific batch number matching the vial you received, reports HPLC purity as a percentage (reputable vendors target ≥98%), and includes a mass spectrometry identity confirmation showing the molecular mass matches the target peptide. Without a COA, you have no evidence beyond the vendor's word that the vial contains what the label says at any particular purity level. The COA is effectively the peptide supply chain's only verifiable trust infrastructure. Missing COAs, missing batch numbers, missing mass spectrometry data, or mismatched batch information across shipments are all dispositive red flags warranting vendor avoidance.

HPLC-only vendors are a documented cost-cutting pattern that practitioner audits consistently flag. HPLC measures purity — it answers 'how pure is the primary compound in this vial?' — but it cannot confirm the compound's identity. A vendor showing an HPLC result at 98% purity is saying 'something 98% pure is in this vial' without proving what that something actually is. Mass spectrometry is the identity verification step, confirming the molecular mass matches the target peptide. Substitution scams where a vendor ships a cheaper peptide under a more expensive peptide's label are detectable only through MS. A legitimate complete COA includes both HPLC and MS. Vendors offering HPLC-only COAs are either cutting corners on QA infrastructure or deliberately obscuring identity verification. Either way, the trust signal is negative enough that practitioner consensus is to avoid them for anything beyond low-stakes experimentation.

Fraudulent COAs have characteristic tells. First, check batch consistency — legitimate COAs have distinct batch numbers per production lot; fake COAs often reuse the same batch number across multiple shipments or show numeric inconsistencies between the vial label and the COA. Second, verify with the testing lab directly. Legitimate third-party labs will confirm or deny that they tested a specific batch on a specific date. A vendor that refuses to disclose the lab or provides a lab that declines to verify is a dispositive red flag. Third, inspect COA formatting — real lab reports have consistent letterhead, consistent data formatting, and chain-of-custody metadata; photoshopped COAs typically show artifacting around batch numbers and dates. Fourth, cross-reference across shipments — a vendor whose COAs improve in quality after customer pressure is telling you something important about baseline practice. DoseCraft's vendor scoring incorporates COA verification as a primary input.

Price variance reflects three underlying factors: synthesis difficulty, QA infrastructure cost, and vendor business model. Short-chain peptides (under 30 residues) synthesize cleanly and cheaply; long-chain peptides and compounds with difficult residue patterns cost dramatically more to produce at high purity. Vendors maintaining rigorous third-party testing, cold-chain infrastructure, and transparent customer support carry higher operating costs than cut-rate operators and price accordingly. Extremely low prices compared to the market median are typically achieved by cutting on testing (HPLC-only or no testing), cutting on cold chain (ambient shipping that arrives warm), or cutting on product quality (underweight vials, batch variance). Midrange pricing typically indicates legitimate QA infrastructure; premium pricing often reflects additional brand margin rather than additional quality. Unusually low prices warrant scrutiny rather than celebration — the savings are coming from somewhere, and usually that somewhere is QA.

Established research peptide vendors accept multiple payment rails: credit card (frequently through alternative processors, since mainstream processors frequently reject peptide merchants), bank transfer, cryptocurrency (Bitcoin, USDC, Monero), and occasionally e-check or money order. Reputable vendors support crypto as one option among several. Vendors accepting only cryptocurrency with no alternative payment channel is a common red flag — it can indicate the vendor has been rejected by every traditional processor for merchant-risk reasons or is deliberately operating outside the reachable financial system. Credit card payments carry chargeback protection (a strong signal of vendor confidence), though fees are higher and some vendors discount for crypto or bank transfer. For larger orders, bank transfer is common and often discounted. Researchers should match payment method to order size and vendor familiarity — a first order on credit card with a new vendor preserves recourse if shipment fails.

A bad batch — visible degradation in the lyophilized powder, reconstitution that doesn't clear, unexpected discoloration, unusual shipping condition (arrived warm, cracked vial, damaged seal), or downstream observed potency failure — warrants immediate vendor contact with photographic documentation. Reputable vendors replace genuinely bad batches without dispute; their cold-chain and QA processes assume occasional failure and they price accordingly. Document everything: photograph the shipping container, the vial condition, any visible issue, and the shipping label with timestamp. Preserve the vial rather than discarding it in case the vendor requests return or additional inspection. Cross-reference the batch number against the COA to confirm the documentation matches the physical product. Low-quality vendors deflect, delay, or require extensive argumentation — this response pattern itself is useful signal for vendor trust scoring. DoseCraft's inventory tool logs batch numbers and condition photos per vial so bad-batch documentation is captured automatically at receipt.

Research-use-only peptides are not controlled substances under the Controlled Substances Act, so domestic US shipments of RUO-labeled research chemicals are not generally targeted for interception in the way that CSA-scheduled substances are. Import from international vendors is a different regulatory context — customs can hold or refuse import of compounds flagged as pharmaceutical or requiring FDA approval, and some specific peptides are on watchlists depending on compound and country of origin. Domestic vendors shipping research-labeled product within the US have low interception risk when the shipment is properly labeled and declared. International shipments, vague or mislabeled declarations, and compounds with pharmaceutical parallels (compounded pharmaceutical Semaglutide, for example) carry more regulatory attention. Reputable vendors understand shipping regulations and label accordingly; vendors that obscure shipping contents or use deceptive declarations create compliance exposure for both seller and recipient.

Practitioner-reported side effects of BPC-157 are generally mild and uncommon at standard research doses. The most frequently reported effects are transient injection site reactions (redness, minor soreness, occasional small bruising), mild fatigue during active repair windows, and occasional reports of vivid dreams or altered sleep patterns. Some researchers report lightheadedness on initial dosing that resolves after the first few sessions. Unlike GLP-1 analogs or anabolic compounds, BPC-157 does not have a well-characterized severe side-effect profile in the available research literature. The compound's safety signal in preclinical and practitioner contexts is relatively strong, though it's worth emphasizing this is research-context information drawn from practitioner audits rather than rigorous human clinical trial data. Baseline bloodwork before a protocol and periodic mid-cycle bloodwork remain the standard approach to catching any unexpected drift.

Some peptides can interact meaningfully with cardiovascular medication, and decisions in this context should involve a clinician familiar with both the compound and the researcher's baseline. GLP-1 analogs can lower blood pressure modestly through their weight-reduction mechanism, which can compound effects of ACE inhibitors, ARBs, or beta blockers. Growth-hormone-axis peptides can shift fluid balance and cardiac output. BPC-157 and repair peptides have no well-documented cardiovascular interaction profile at research doses but the data is limited. The practitioner-consensus approach: comprehensive baseline bloodwork including cardiovascular markers, conservative initial dosing with close monitoring, and clinician involvement before starting protocols when any meaningful prescription medication is in play. This is especially true for anyone on multiple medications or with documented cardiovascular history. DoseCraft's interaction checker flags known interaction concerns, though it cannot substitute for clinician review.

Most research peptides have been studied primarily in male cohorts, and this gender asymmetry in the evidence base creates genuine uncertainty for female researchers. GLP-1 analogs have substantial female clinical trial data and behave similarly across genders. Growth-hormone-axis peptides can interact with reproductive hormones and should be approached carefully by women of reproductive age; practitioner protocols often use lower doses and avoid use during any pregnancy-possible window. Healing peptides like BPC-157 and TB-500 have limited female-specific data but practitioner use is widespread without characteristic gender-specific concerns. Dose adjustment for body mass is straightforward. Pregnancy and breastfeeding are hard exclusions for nearly all research peptides — the data is insufficient and the risk-benefit calculation is not appropriate for self-directed research. Female researchers should seek out female-specific practitioner reports and clinical data where available; DoseCraft's practitioner corpus captures gender-differential data points when they exist in the source material.

Overdose severity varies dramatically by compound class. GLP-1 analog overdose typically produces severe nausea, vomiting, dehydration, and occasionally hypoglycemia — unpleasant but generally not life-threatening at the research-accessible dose range, though serious overdose can require supportive medical care. Growth-hormone-axis peptide overdose can produce acute fluid retention, joint pain, and insulin resistance; severe cases warrant medical evaluation. Healing peptides and nootropic peptides generally have a wide therapeutic window and dose-related side effects are typically modest even at multiples of standard dose. Any suspected significant overdose — particularly one producing cardiovascular, respiratory, or neurological symptoms — warrants immediate medical attention regardless of compound. The practical lesson is the reverse: dose errors are overwhelmingly more likely to be under-dosing from math errors than genuine overdose, but the protection against both is careful calculation and conservative titration. DoseCraft's dose calculator specifically catches the unit-scale errors that produce accidental 10x overdoses.

Alcohol interacts with several peptide classes in meaningful ways. GLP-1 analogs reduce alcohol tolerance and in some researchers reduce alcohol craving substantially — this is a reported effect that practitioner audits capture. Drinking during GLP-1 protocols also amplifies the gastric side-effect profile, making nausea more likely and more severe. Growth-hormone-axis peptides are blunted by alcohol's effect on pituitary function, so drinking close to GH-related peptide dosing reduces protocol effectiveness. Healing peptides have less documented alcohol interaction but any inflammatory load from alcohol works against the repair signaling the peptides are meant to support. The practitioner consensus across classes is that moderate, infrequent alcohol is generally compatible with most peptide research but heavy drinking undermines protocol outcomes and amplifies side-effect exposure. Researchers serious about protocol data quality typically reduce alcohol substantially during active cycles.

No — most research peptides are prohibited under the World Anti-Doping Agency (WADA) code and the equivalent codes of most major sports bodies (NCAA, MLB, NFL, UFC). The S2 Peptide Hormones, Growth Factors, and Related Substances category is broadly drawn and covers growth hormone secretagogues, GHRH analogs, IGF-1 related compounds, and many healing peptides including BPC-157 and TB-500. Even compounds with legitimate medical applications (Semaglutide, Tirzepatide) can appear on sport-specific prohibited lists for specific competition windows. WADA testing is increasingly sensitive and some peptides remain detectable for weeks beyond last dose. Competitive athletes in tested sports should treat research peptides as disqualifying regardless of their legal status for general research purposes. Non-tested recreational use is a different context entirely, but the anti-doping framework does not distinguish 'research use' from 'performance-enhancing use' for purposes of sanction.

The question is compound-specific and mechanism-specific. Peptides that promote cell proliferation, angiogenesis, or telomerase activation share mechanisms that can theoretically accelerate existing malignancies even if they don't initiate new ones. Growth-hormone-axis peptides have decades of research addressing this concern; the current consensus is that they do not appear to initiate cancer but can accelerate growth of existing malignancies, which is why baseline oncology screening is sensible before longer protocols. BPC-157 and TB-500 share angiogenesis mechanisms with tumor vascularization, and while there is no documented cancer induction, cautious use in researchers with cancer history is the practitioner-consensus approach. Telomerase-activating compounds like Epitalon carry inherent theoretical risk because telomerase activation is a hallmark of many cancer cells. GLP-1 analogs have extensive clinical trial surveillance with generally reassuring cancer safety profiles. Baseline and periodic bloodwork including relevant tumor markers is standard practice for longer protocols.

Baseline comprehensive bloodwork before any multi-week protocol is practitioner-consensus standard. The core panel: CBC (complete blood count), CMP (comprehensive metabolic panel covering liver and kidney function), lipid panel, HbA1c and fasting glucose, fasting insulin, thyroid panel (TSH, free T3, free T4), and testosterone/estradiol for relevant compounds. Add IGF-1 and IGFBP-3 for growth-hormone-axis protocols, prolactin for GH-related compounds, and tumor markers (PSA for men, CA-125 for women) for longer protocols with angiogenesis mechanisms. Mid-cycle bloodwork at week 4–6 catches drift before it becomes a problem; end-of-cycle bloodwork documents total impact; mid-off-cycle bloodwork establishes the baseline for the next cycle. This pattern applies across compound classes — the specific markers that matter shift, but the baseline/mid/end/off rhythm is universal practitioner practice. DoseCraft's bloodwork tracking captures longitudinal trends and flags drift that single-snapshot comparison misses.

Head-to-head clinical trial data (SURPASS-2 and related studies) shows Tirzepatide producing superior weight reduction and glucose effects compared to Semaglutide at matched dosing schedules. Tirzepatide's dual GLP-1 plus GIP receptor agonism appears to drive the difference — the GIP component enhances adipose tissue lipid handling and amplifies GLP-1 receptor sensitivity, producing synergistic rather than additive effects. That said, 'better' depends on research context. Semaglutide has longer clinical trial history, more extensive cardiovascular outcome data, and typically lower per-dose cost. Tirzepatide is the more potent tool but the longer-term safety surveillance data base is shallower simply because the compound is newer. Practitioner protocols in research contexts commonly default to Tirzepatide for researchers prioritizing effect magnitude and to Semaglutide for researchers prioritizing established safety profile and cost efficiency. Both are being researched for expanding indications beyond initial weight and glucose applications.

Retatrutide is an investigational triple receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneously. It represents the current research frontier beyond Tirzepatide's dual-agonist architecture. The glucagon receptor component is particularly interesting mechanistically — glucagon signaling increases energy expenditure, which theoretically amplifies the caloric deficit produced by appetite suppression alone. Phase 2 trial data published in 2023 showed weight reduction in the range of 22–24% at 48 weeks, which exceeds the magnitude observed with Tirzepatide over equivalent time windows. Phase 3 trials are ongoing. Retatrutide is not FDA-approved for any indication as of current status and is only available through research-use-only channels. Practitioner experience with Retatrutide is still early-stage and long-term safety profile data is limited. DoseCraft's compound library tracks emerging research peptides including Retatrutide as clinical trial data matures.

GLP-1 protocols in research contexts typically show measurable weight change within the first 4–6 weeks of titrated dosing, with the rate of change accelerating as titration reaches maintenance dose. Published clinical trial data suggests approximately 5–8% body weight reduction at 12 weeks and 15–20% at 48–68 weeks with full-dose Semaglutide or Tirzepatide. Rate varies substantially by starting body composition, caloric baseline, activity level, and individual response — some researchers are rapid responders showing faster initial change, while others require longer exposure at maintenance dose for measurable effect. Slow early response is not indicative of non-response; meaningful weight dynamics often emerge between weeks 8–16 as the GLP-1 pathway fully engages. The rate of weight change is not the right KPI — body composition change, metabolic marker drift, and subjective appetite regulation are all more informative than the scale. DoseCraft's weekly AI reports correlate these metrics to surface the actual trajectory.

The dominant GLP-1 side-effect cluster is gastrointestinal: nausea, early satiety, delayed gastric emptying (sometimes experienced as food feeling 'stuck'), occasional vomiting especially during rapid titration, diarrhea or constipation. These effects are dose-dependent and titration-sensitive — researchers who titrate too quickly experience substantially more severe GI symptoms than researchers who respect the conventional 4-week step intervals. Less common but documented effects include injection-site reactions, fatigue during early titration, transient headaches, and occasional mood or sleep changes. Severe effects are rare and warrant medical attention: persistent severe vomiting, signs of dehydration, severe abdominal pain (pancreatitis risk), and jaundice (hepatic concern). GLP-1 analogs also cause gallbladder concerns in some researchers, particularly those with existing gallbladder disease or rapid weight loss trajectories. Baseline bloodwork and conservative titration remain the primary risk-management levers.

Established Semaglutide titration follows the Wegovy clinical trial schedule: 0.25mg weekly for weeks 1–4, 0.5mg weekly for weeks 5–8, 1mg weekly for weeks 9–12, 1.7mg weekly for weeks 13–16, and 2.4mg weekly as the final maintenance dose from week 17 onward. The 4-week step intervals are not arbitrary — they reflect the time GLP-1 receptors and downstream gastric adaptation need to adjust to each new exposure level. Researchers who compress the schedule experience dramatically more severe GI side effects without faster outcome trajectory. Some practitioners extend steps if GI side effects are intolerable at a given dose, holding at the tolerated dose for an additional 2–4 weeks before advancing. Conservative titration with full 4-week step intervals produces the smoothest protocol. DoseCraft's protocol engine generates per-researcher Semaglutide titration schedules and tracks tolerance feedback to guide escalation.

Stacking Semaglutide with Tirzepatide is not practitioner-consensus practice. Both compounds saturate the GLP-1 receptor — adding Semaglutide on top of Tirzepatide produces no meaningful additional GLP-1 activation because the receptor is already occupied, but does compound gastric side-effect exposure and increase total receptor exposure beyond studied ranges. Tirzepatide already covers GIP receptor agonism that Semaglutide doesn't reach, so there's no complementary mechanism to stack. Researchers who want more effect than Tirzepatide alone produces typically increase Tirzepatide dose within the studied titration range rather than adding a second GLP-1 compound. Emerging research peptides like Retatrutide add new mechanisms (glucagon agonism) that Tirzepatide doesn't cover, which represents a different stacking logic — single-compound triple agonism rather than polypharmacy. Practitioner audits generally recommend monotherapy or a single titration within one compound rather than GLP-1 polypharmacy stacking.

The contemporary practitioner view has shifted toward indefinite GLP-1 use rather than cycled protocols for researchers pursuing long-term weight and metabolic research. The original cycling argument assumed receptor desensitization would compromise long-term effectiveness, but clinical trial data through 3+ years of continuous Semaglutide use has not demonstrated meaningful receptor desensitization at therapeutic doses. Indefinite use with dose taper for specific circumstances appears to produce more stable outcomes than on/off cycling, which in clinical trials correlates with weight regain during off-periods. Longer-term safety surveillance data continues to accumulate; the currently available evidence supports extended use with periodic bloodwork monitoring. Researchers choosing eventual discontinuation should plan for metabolic adaptation management rather than expecting sustained effect post-discontinuation. DoseCraft's long-term tracking is designed for multi-year GLP-1 protocols rather than assuming short cycles.

Discontinuation of GLP-1 analogs produces predictable physiologic rebound. Appetite regulation returns to pre-protocol patterns over roughly 2–8 weeks as the compound clears and GLP-1 receptor signaling returns to endogenous baseline. Clinical trial data suggests approximately two-thirds of weight lost during a GLP-1 protocol is regained within 1–2 years of discontinuation if no structural behavior change was implemented during the protocol window. Metabolic markers (HbA1c, fasting insulin, lipid panel) similarly drift back toward pre-protocol values without sustained intervention. This is not a 'rebound effect' in the pharmacological sense — it's the natural return of the physiology the compound was masking. Researchers planning discontinuation should use the protocol window to build sustainable caloric patterns, activity patterns, and metabolic habits rather than relying on the compound's appetite effect to be permanent. DoseCraft's off-cycle tracking supports transition-period monitoring.

DoseCraft is a pharmacokinetic-aware AI copilot for peptide research. The platform combines a 90+ compound library, an AI protocol engine that models half-life decay and interaction overlap across stacks, vendor trust scoring integrated at the compound level, and a practitioner-sourced knowledge corpus representing 10,000+ hours of clinician-validated protocols. Researchers use DoseCraft to design protocols with real PK math rather than static dose calculators, to log doses and bloodwork with structured data capture, and to see weekly AI reports that correlate subjective response with dose patterns to identify what's actually driving results. The underlying thesis is that peptide research has outgrown spreadsheets and forum threads — the volume, variety, and complexity of compounds now in research use require analytical infrastructure that previous-generation tools don't provide. DoseCraft is that infrastructure.

No. Most peptide apps are logging surfaces — you enter what you took and they display it back. DoseCraft is a reasoning layer. The AI protocol engine models half-life decay curves per compound, surfaces interaction overlap across multi-compound stacks, and generates titration schedules from compound-specific pharmacokinetic data. The vendor trust score layer integrates sourcing quality directly into the compound library so researchers see trust context at protocol-design time rather than in a separate research process. The practitioner corpus provides knowledge grounded in actual clinical protocols rather than PubMed abstracts (too narrow) or Reddit threads (too noisy). Weekly AI reports correlate logged data to produce actionable insight rather than static dashboards. The architectural difference is structural: every other peptide app logs what you took; DoseCraft answers what to change and why. Get the full answer inside DoseCraft Pro.

PeptIQ is the closest competitor in the AI-powered peptide tracking space. The structural differences: DoseCraft's knowledge corpus is 10,000+ hours of practitioner-validated protocols versus PeptIQ's PubMed abstract grounding; DoseCraft models PK math (half-life decay, interaction overlap) versus PeptIQ's static dose calculator; DoseCraft includes vendor trust scoring as a core feature (PeptIQ has none); DoseCraft's compound library covers 90+ compounds with three-lane evidence tagging versus PeptIQ's ~40 partial entries. DoseCraft's pricing structure offers a Core tier at $9.99/month for library plus tracker and Pro at $19.99/month for the full AI protocol engine — matching PeptIQ's single $19.99 price point while providing substantially deeper feature architecture. DoseCraft is for researchers who've outgrown the spreadsheet-plus-chatbot stage and want analytical infrastructure comparable to what serious clinical practices use.

No. DoseCraft is a software platform — we don't manufacture, distribute, or sell peptides. The vendor trust scoring integrated into the compound library is evaluative infrastructure, not a sales funnel. We assess vendors across COA quality, batch consistency, cold-chain integrity, payment legitimacy, and aggregated community feedback, and we surface that data inside the app so researchers can make informed sourcing decisions. This separation is structural: a peptide tracker that also sold peptides would have irreducible conflicts of interest in every vendor rating. By not selling product, DoseCraft can publish vendor scores that reflect honest assessment rather than commercial incentive. Researchers use DoseCraft for protocol design, tracking, and analytical infrastructure; they source product through vetted vendors whose trust scores surface inside the app.

The AI Protocol Engine takes a research target, a researcher baseline, and compound library context, and generates a structured protocol recommendation. Specifically, it models half-life decay per compound to produce dosing frequency recommendations that maintain steady-state tissue exposure, calculates interaction overlap across multi-compound stacks to surface redundancy or mechanism complementarity, generates titration schedules where compound-specific data warrants stepped dosing, and flags contraindication patterns based on baseline bloodwork and concurrent compound use. Unlike ChatGPT wrappers that generate plausible-sounding text without underlying math, DoseCraft's engine runs real pharmacokinetic computation grounded in the practitioner corpus and published PK literature per compound. Weekly AI reports close the loop by correlating logged dose data with subjective and bloodwork outcomes to identify what's driving results. Get the full answer inside DoseCraft Pro.

Yes. DoseCraft operates on a strict privacy-first architecture. Protocol data, bloodwork uploads, dose logs, and personal identifiers are encrypted in storage and in transit. We don't sell user data. We don't share data with advertisers. We don't use researcher data to train AI models that serve other users. Aggregated anonymized statistics may inform platform-level features (for example, broad trends in compound usage or titration success rates), but these are computed from de-identified data without individual attribution. Account deletion permanently removes associated data from our systems. Bloodwork uploads are retained only for the researcher's own longitudinal view and are never published or shared. This architecture is structural rather than policy-only: the system is designed so that data flow out of an individual researcher's account cannot occur by mistake or unauthorized access.

DoseCraft offers two tiers. The Core tier at $9.99 per month includes full access to the 90+ compound library, dose logging, inventory tracking, reconstitution calculator, and the three-lane evidence tagging system. The Pro tier at $19.99 per month adds the AI Protocol Engine, weekly AI-generated insight reports correlating dose patterns with outcomes, the interaction checker for multi-compound stacks, priority support, and advanced bloodwork tracking with trend analysis. Annual billing offers a meaningful discount on both tiers. The pricing deliberately undercuts comparable platforms — PeptIQ charges $19.99 for what DoseCraft offers at $9.99 Core, and DoseCraft Pro at the same $19.99 price point provides substantially deeper feature architecture. The pricing philosophy is that serious analytical infrastructure should be accessible rather than gated — researchers shouldn't need clinic-tier pricing to get clinical-tier tooling.

Yes. DoseCraft offers a free trial that gives full access to Core tier features — the complete compound library, dose logging, inventory tracking, and reconstitution calculator — so researchers can evaluate whether the platform fits their workflow before committing. Pro tier features including the AI Protocol Engine are available during the trial window so researchers can specifically evaluate the AI-powered analytical layer that differentiates DoseCraft. No credit card is required to start, and there is no automatic conversion to paid tier at trial end — researchers choose whether to subscribe and on which tier. The intent is to give researchers enough hands-on time with the full platform to make an informed decision about ongoing use. Start at app.dosecraftapp.com/auth/signup.